{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fostamatinib+Disodium", "query": { "intervention": "Fostamatinib Disodium" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 23, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fostamatinib+Disodium&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T11:04:40.754Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03764618", "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Warm Antibody Autoimmune Hemolytic Anemia" ], "interventions": [ { "name": "Fostamatinib disodium", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rigel Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 90, "start_date": "2019-04-24", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2023-05-25", "last_synced_at": "2026-09-04T11:04:40.754Z", "location_count": 26, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03764618" }, { "nct_id": "NCT00798096", "title": "Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T Cell Lymphoma" ], "interventions": [ { "name": "Fostamatinib Disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rigel Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2009-03", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2016-09-19", "last_synced_at": "2026-09-04T11:04:40.754Z", "location_count": 8, "location_summary": "San Francisco, California • Stanford, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00798096" }, { "nct_id": "NCT01197534", "title": "Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "fostamatinib", "type": "DRUG" }, { "name": "placebo, fostamatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 913, "start_date": "2010-09", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-04-17", "last_synced_at": "2026-09-04T11:04:40.754Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01197534" }, { "nct_id": "NCT01264770", "title": "Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Fostamatinib and placebo injections", "type": "DRUG" }, { "name": "Adalimumab and placebo of fostamatinib", "type": "DRUG" }, { "name": "Placebo of fostamatinib, fostamatinib, and placebo injections", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 644, "start_date": "2011-01", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-05-06", "last_synced_at": "2026-09-04T11:04:40.754Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01264770" }, { "nct_id": "NCT02612558", "title": "A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Warm Antibody Autoimmune Hemolytic Anemia" ], "interventions": [ { "name": "Fostamatinib 150 mg bid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rigel Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2016-07", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2021-07-21", "last_synced_at": "2026-09-04T11:04:40.754Z", "location_count": 31, "location_summary": "Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 27 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02612558" }, { "nct_id": "NCT04629703", "title": "Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19", "SARS (Severe Acute Respiratory Syndrome)", "SARS Pneumonia", "SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere", "Pneumonia", "Pneumonia, Viral" ], "interventions": [ { "name": "Fostamatinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rigel Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 280, "start_date": "2021-03-25", "completion_date": "2022-09-05", "has_results": false, "last_update_posted_date": "2023-08-18", "last_synced_at": "2026-09-04T11:04:40.754Z", "location_count": 9, "location_summary": "Orange, California • Washington D.C., District of Columbia • Hialeah, Florida + 6 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629703" }, { "nct_id": "NCT01197521", "title": "Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "fostamatinib", "type": "DRUG" }, { "name": "placebo, fostamatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 923, "start_date": "2010-09", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-04-07", "last_synced_at": "2026-09-04T11:04:40.754Z", "location_count": 41, "location_summary": "Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01197521" }, { "nct_id": "NCT01197781", "title": "Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Drug Interactions", "Healthy Volunteers" ], "interventions": [ { "name": "FOSTAMATIN", "type": "DRUG" }, { "name": "Verapamil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 15, "start_date": "2010-09", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2010-11-23", "last_synced_at": "2026-09-04T11:04:40.754Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01197781" }, { "nct_id": "NCT01242514", "title": "Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Fostamatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1917, "start_date": "2011-01", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2014-04-04", "last_synced_at": "2026-09-04T11:04:40.754Z", "location_count": 116, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 113 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01242514" }, { "nct_id": "NCT02077192", "title": "Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Immune Thrombocytopenic Purpura" ], "interventions": [ { "name": "Fostamatinib Disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rigel Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2014-10", "completion_date": "2020-06-02", "has_results": true, "last_update_posted_date": "2023-12-11", "last_synced_at": "2026-09-04T11:04:40.754Z", "location_count": 9, "location_summary": "Tucson, Arizona • Peoria, Illinois • Lafayette, Indiana + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02077192" } ] }